AKT1 and cancer: Given that 10 ng/mL TGF-β1 can activate both the TGF-β/Smad and PI3K/Akt/mTOR pathways to promote EMT in cancer cells, we hypothesized that deactivating these two signaling pathways may reverse EMT in TGF-β-treated HCC cells.